SeaStar Medical Holding (ICU) Income from Continuing Operations (2021 - 2026)
SeaStar Medical Holding's (ICU) quarterly Income from Continuing Operations came in at 3521000.0 in Q1 2026, up 6.65% YoY from 3301320.41 in Q1 2025, and down 21.2% on a QoQ basis from 2905000.0 in Q4 2025.
SeaStar Medical Holding (ICU) Income from Continuing Operations (2021 - 2026) Analysis & Trends
SeaStar Medical Holding (ICU) has 6 years of Income from Continuing Operations data on file, last reported at 3521000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 6.65% year-over-year to 3521000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11900000.0 (up 25.18% YoY) and the FY2025 annual result came in at 12151000.0, up 51.06% from the prior year.
- Income from Continuing Operations fell to 3521000.0 in Q1 2026, from 2905000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 902000.0 in Q2 2022 to a low of 12697000.0 in Q1 2024.
- A 5-year average of 4642588.24 and a median of 3521000.0 in 2026 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 708.35% — and 2025, when it jumped 70.29%.
- Tracing ICU's Income from Continuing Operations over 5 years: stood at 8392000.0 in 2022, then dropped by 12.69% to 9457000.0 in 2023, then jumped by 53.27% to 4419000.0 in 2024, then jumped by 34.26% to 2905000.0 in 2025, then retreated by 21.2% to 3521000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3521000.0 (Q1 2026), 2905000.0 (Q4 2025), and 3472000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | SeaStar Medical Holding | 13.68 Mn | 6.68 Mn | 561,000.00 | -3.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.73 Mn |
| Mar 31, 2026 | -3.52 Mn |
| Dec 31, 2025 | -2.91 Mn |
| Sep 30, 2025 | -3.47 Mn |
| Jun 30, 2025 | -2.00 Mn |
| Mar 31, 2025 | -3.77 Mn |
| Dec 31, 2024 | -4.42 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Jun 30, 2024 | -3.24 Mn |
| Mar 31, 2024 | -12.70 Mn |
| Dec 31, 2023 | -9.46 Mn |
| Sep 30, 2023 | -7.23 Mn |
| Jun 30, 2023 | -2.45 Mn |
| Mar 31, 2023 | -7.10 Mn |
| Dec 31, 2022 | -8.39 Mn |
| Sep 30, 2022 | -1.89 Mn |
| Jun 30, 2022 | -902,000.00 |
| Mar 31, 2022 | -1.00 Mn |
| Dec 31, 2021 | -3.69 Mn |
| Sep 30, 2021 | -408,737.00 |